Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing a new method to prevent the recurrence and spread of solid tumors. The company utilizes pancreatic proenzymes, which are designed to target and eliminate cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. This proenzyme therapy is based on the scientific principle that enzymes, particularly those secreted by the pancreas, stimulate biological reactions and may serve as the body's primary defense against cancer. The company's primary product candidate is PRP, a novel formulation that uses proenzymes, which are inactive precursors of enzymes. Propanc Biopharma, Inc. has observed positive early indications of the anti-cancer effects of its technology and has completed successful pre-clinical studies on PRP. The company has begun preparing for a clinical study involving advanced cancer patients, including the development of its Clinical Study Protocol and Investigator's Brochure. Propanc Biopharma, Inc. has also initiated the study preparation process with a contract research organization (CRO), analytical lab, and trial site selection. The company has started compiling its clinical trial application for PRP (CTA) and plans to submit it in the fourth quarter of the 2026 calendar year. In the first calendar quarter of 2027, the company intends to begin preparing logistics and initiating trial site visits.